Product Description
berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | China | Hong Kong | India | Korea | New Zealand | Russia | Taiwan | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: HighTide Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Armenia, China, Sweden
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Type 2 Diabetes
Phase 1: Gastroenteritis|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EP-1007 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-11-01 |
69% |
| HTD1801.PCT109 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2025-07-01 |
9% |
| Symphony2 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2025-03-01 |
7% |
| Symphony1 | P3 |
Active, not recruiting |
Type 2 Diabetes |
2025-03-01 |
7% |
| CTR20234184 | P1 |
Completed |
Healthy Volunteers |
2024-07-19 |
|
| CTR20244648 | P1 |
Recruiting |
Gastroenteritis |
None |